|
Lung Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.
|
28191284 |
2016 |
|
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.
|
28191284 |
2016 |
|
Malignant neoplasm of lung
|
0.300 |
Biomarker
|
disease |
CTD_human |
The bioinformatics data indicate that co-expression of both c-Myc and Pirh2 strongly correlated with poor survival of lung cancer patients.
|
28191284 |
2016 |
|
Sciatic Neuropathy
|
0.200 |
Biomarker
|
disease |
RGD |
Dynamic changes of PIRH2 and p27kip1 expression in injured rat sciatic nerve.
|
21959983 |
2012 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
|
22491018 |
2013 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
|
22491018 |
2013 |
|
Lymphocyte Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
The combination of a genome-wide association study of lymphocyte count and analysis of gene expression data reveals novel asthma candidate genes.
|
22286170 |
2012 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Decrease of PIRH2 expression in the breast cancer cell line MDA-MB-231 resulted in reduced tumor cell growth via the inhibition of cell proliferation and the interruption of cell cycle transition.
|
27393961 |
2016 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Pirh2 protein expression correlated with tumor grade and stage (P < 0.001 and P < 0.001 respectively).
|
23102595 |
2013 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Pirh2 is a Ring-H2 domain containing E3 ubiquitin ligase that targets several important tumor suppressor genes for proteasomal degradation.
|
22570270 |
2012 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.
|
21852228 |
2011 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Collectively, our data reveal the in vivo roles of Pirh2 in the regulation of p53 and c-Myc stability and support its role as a tumor suppressor.
|
22125490 |
2011 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Thus, Axin is a critical determinant in p53-dependent tumour suppression in which Pirh2 and Tip60 have different roles in triggering cell-cycle arrest or apoptosis depending on the severity of genotoxic stress.
|
19731416 |
2009 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Together, our data suggest that phosphorylation of Pirh2 may act as a fine-tuning to maintain the balance of p53-Pirh2 autoregulatory feedback loop, which facilitates the tight regulation of p53 stability and tumor suppression.
|
17568776 |
2007 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Several novel findings were obtained: (i) cytoplasmic p27 was observed in 8.6%, most frequently in SCC (13.3%), and correlated with nodal metastasis (P=.0044), (ii) significant inverse correlation between nuclear p27 and Pirh2 expression was observed by statistical analysis and at the cellular level, and (iii) cytoplasmic Pirh2 and total (cytoplasmic and/or nuclear) Pirh2 were significantly correlated with the nodal status (P=.0225, 0.0314), the pathological stage (P=.0213, 0.0475) and recurrence-free survival (P=.0194, 0.0482, respectively) in AC.
|
28601655 |
2017 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Decrease of PIRH2 expression in the breast cancer cell line MDA-MB-231 resulted in reduced tumor cell growth via the inhibition of cell proliferation and the interruption of cell cycle transition.
|
27393961 |
2016 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
However, the molecular mechanism of Pirh2 activation in tumorigenesis still remains poorly understood.
|
22570270 |
2012 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of Pirh2 is frequently detected in many clinical tumor tissues including hepatocellular carcinoma (HCC).
|
22570270 |
2012 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We also report that low expression of human PIRH2 in lung, ovarian, and breast cancers correlates with decreased patients' survival.
|
22125490 |
2011 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Consistent with the role p53 plays in suppressing c-Myc-induced oncogenesis, its deficiency exacerbates tumorigenesis of Pirh2(-/-) mice.
|
22125490 |
2011 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
A low level of expression of hPirh2 was found both at transcriptional and translational level in human hepatocellular carcinoma (HCC) when compared to non-cancerous tissue.
|
20452352 |
2010 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, overexpression of hPIRH2 protein was detected in 73 of 82 (89%) resected prostate cancers, with a strong correlation between increased hPIRH2 expression and aggressive disease, as signified by high Gleason sum scores and the presence of metastatic disease (P = <0.0001 and 0.0004, respectively).
|
16914734 |
2006 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Avenanthramide A Induces Cellular Senescence via miR-129-3p/Pirh2/p53 Signaling Pathway To Suppress Colon Cancer Growth.
|
30888162 |
2019 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Avenanthramide A Induces Cellular Senescence via miR-129-3p/Pirh2/p53 Signaling Pathway To Suppress Colon Cancer Growth.
|
30888162 |
2019 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to highlight the role of p53-induced RING-H2 (Pirh2) in the acquisition of bortezomib resistance in MM and to clarify the function and mechanism of action of Pirh2 in MM cell growth and resistance, thereby providing the basis for new therapeutic targets for MM.
|
29441489 |
2018 |